Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
drugs
5
×
life sciences
national blog main
boston blog main
clinical trials
alnylam pharmaceuticals
boston
boston top stories
fda
rna interference
aminolevulinic acid
biotech
givosiran
paul matteis
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akin akinc
alirocumab
amgen
cannabidiol
crispr
cystic fibrosis
cystic fibrosis foundation
dravet syndrome
epidiolex
evercore isi
evolocumab
fen-phen
fenfluramine
gilead sciences
gw pharmaceuticals
heart attack
hepatitis c
incivek
inclisiran
jeff leiden
joseph swartz
kayldeco
lennox-gastaut syndrome
What
pharmaceuticals
5
×
drug
alnylam
data
medicine
rna
ago
fda
interference
market
medicines
new
rnai
second
seek
speedy
weeks
approval
approved
based
battle
cannabis
cf
cholesterol
cleared
crisis
cystic
derivative
developer
epilepsy
evidence
far
fibrosis
force
form
gw
gw’s
heart
helped
indicated
Language
unknown
Current search:
pharmaceuticals
×
drugs
×
@xconomy.com
4 years ago
Jeff Leiden, Who Shaped Vertex Into a CF Force, to Switch Roles
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug